Developer docs
API playgroundTry for free, no card

Search company profiles

CeQur Simplicity

Full company profile

uuid0000p6m

Namestring
CeQur Simplicity
Legal namestring
CeQur SA
Company typeenum
Private
Founded yearint
2018
Descriptiontext

CeQur Simplicity is a privately held medical device company that designs, manufactures, and commercializes a wearable, disposable bolus insulin delivery patch for adults aged 21 and older with Type 1 or Type 2 diabetes who are on multiple daily injection (MDI) regimens. The company's core technology is a thin, low-profile patch that delivers rapid-acting mealtime insulin via a hidden, flexible cannula, eliminating the need for needle handling at each meal. The device holds 15 patents covering its bolus-only architecture, dosing lock safety mechanism, hidden cannula insertion, and two-button user interface, and is FDA 510(k)-cleared for up to 7 days of continuous wear with the most recent clearance extending wear duration from 4 days and adding a 1-unit dosing variant for more precise titration. The patch is compatible with Eli Lilly's Humalog (insulin lispro) and Novo Nordisk's NovoLog (insulin aspart) U-100 rapid-acting insulin analogues, which patients fill into the device themselves.

The company operates a prescription-based, pharmacy-benefit commercial model in the United States. Revenue is generated through hardware sales of the patch (sold as an 8-pack), dispensed via retail pharmacies with coverage on more than 85% of claims as a pharmacy benefit as of mid-2026. Commercial distribution combines an expanding US field sales force targeting endocrinologists, primary care physicians, and certified diabetes educators; clinical diabetes specialists supporting prescriber education; and the CeQur Cares inside-sales patient support team handling onboarding, insurance navigation, and copay enrollment (commercially insured patients can access a savings card limiting out-of-pocket to under $35 per month). Government channel sales to the VA and DoD are executed through Lovell Government Services, a Service-Disabled Veteran-Owned Small Business partner.

CeQur is headquartered in Horw, Switzerland, with US operational headquarters in Greenville, South Carolina, and a 40,000 sq ft automated cleanroom manufacturing facility in Marlborough, Massachusetts, completed in Q4 2024 with capacity to support 100,000 patients. The company has raised more than $335 million across five equity rounds, including a $100 million Series C5 in April 2021, a $120 million equity financing in January 2025, and a $100 million Series E in June 2026 led by Sanofi Ventures. More than 6,000 patients were actively using the device by mid-2025, and the patch has cumulatively replaced more than 10 million mealtime injections since launch. The commercial organization is led by CEO Bradley Paddock (appointed June 2019), CFO Mike Rubino, Chief Commercial Officer Lisa Furnish, and VP of Sales Darin Row (joined March 2025 from Dexcom).

Short descriptiontext

CeQur Simplicity is a private medical device company offering a wearable bolus insulin delivery patch for adults with Type 1 or Type 2 diabetes on multiple daily injections. The FDA-cleared device is dispensed via US retail pharmacies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHorw, Switzerland
HQ citystring
Horw
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable insulin patch, mealtime insulin delivery, diabetes medical device, bolus insulin patch, FDA cleared insulin delivery
Industry1 code
PRIMARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Wearable Insulin Delivery Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Insulin Delivery Device — Prescription Medical Device Sales
TypeHardware Sales
Description

CeQur generates revenue primarily through the sale of its Simplicity bolus insulin delivery patch. The device is a prescription-only Class II medical device dispensed through retail pharmacies. Patients obtain the device via prescription from their healthcare provider and fill it at a pharmacy. Revenue is driven by prescription volume, patient adherence, and payer coverage. Commercial insurance, Medicare Part D, and cash-pay patients all contribute.

myceqursimplicity.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details2 tiers
1Standard prescription — retail pharmacy (commercial insurance)
ModelUnit PricingBilling cadenceMonthly
Notes

Commercially insured patients may use a copay savings card to pay less than $35 per month for a 30-day supply plus a $5 one-time inserter. Without insurance or for patients without coverage, pricing is not publicly disclosed.

myceqursimplicity.com
2Standard prescription — retail pharmacy (uninsured / cash pay)
ModelUnit PricingBilling cadenceMonthly
Notes

Pricing for uninsured or cash-pay patients is not publicly disclosed. The device requires a prescription and is dispensed through pharmacy channels.

myceqursimplicity.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CeQur Simplicity develops and manufactures a wearable, disposable bolus insulin delivery patch designed to replace multiple daily mealtime injections for adults with Type 1 or Type 2 diabetes. The device delivers rapid-acting insulin (Humalog or NovoLog) on demand via a hidden flexible cannula using a simple two-button interface, with FDA-cleared wear durations of up to 7 days.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • A1C reduction of 1.7% in adults with Type 1 or Type 2 diabetes on multiple daily injections
+1 more record
Product overview1 text field

CeQur Simplicity is a single-product medical device company offering the CeQur Simplicity wearable insulin patch as its core product. The portfolio consists of the CeQur Simplicity patch (available in 2-unit and 1-unit dosing variants, with wear duration extended from 4 to 7 days), the reusable Inserter accessory, and the CeQur Cares patient support program. The patch is filled by users with their own prescribed rapid-acting insulin (Humalog U-100 or NovoLog U-100) and delivers on-demand bolus insulin subcutaneously via a flexible cannula. The company also offers a copay savings card for commercially insured patients. The product is sold as an 8-pack of 4-day patches (now expanding to 7-day variants) and is covered as a pharmacy benefit by most commercial and Medicare Part D plans.

Product and service3 records
1CeQur Simplicity Wearable Insulin Patch
CategoryInsulin Delivery Devices
Description

A disposable wearable patch that delivers mealtime and correction bolus insulin via a soft, flexible cannula. Users fill the patch with up to 200 units of rapid-acting insulin (Humalog U-100 or NovoLog U-100) and self-administer 2-unit doses by squeezing two buttons. The patch is FDA-cleared for wear up to 7 days and eliminates the need for multiple daily injections.

2CeQur Simplicity 1-Unit Dosing Device
CategoryInsulin Delivery Devices
Description

A variant of the CeQur Simplicity patch delivering 1-unit increments of rapid-acting insulin for more precise titration in patients requiring tighter glycemic control or lower mealtime insulin doses.

3CeQur Simplicity Inserter
CategoryInsulin Delivery Device Accessory
Description

A reusable handheld device used to apply the CeQur Simplicity patch to the abdomen. Measures 3.7 inches long, 2.2 inches wide, and 1.8 inches high, weighing 2.5 ounces, and is cleanable with soapy water.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Lovell Government Services is a Service-Disabled Veteran-Owned Small Business (SDVOSB) that serves as CeQur's channel partner for sales into the Veterans Affairs (VA) and Department of Defense (DoD) healthcare systems. CeQur has partnered with Lovell to expand access to the Simplicity bolus insulin delivery patch for eligible veterans and active-duty military patients with diabetes managed on multiple daily injections. The partnership enables CeQur to comply with government contracting requirements and access a specialized distribution channel.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Maker of the Omnipod tubeless patch pump, the closest direct competitor to CeQur in the wearable insulin delivery category. Omnipod 5 is an integrated AID system, while CeQur is bolus-only — both target patients seeking tubeless, on-body insulin delivery via patch form factor.

TypeDirect peer
Description

Manufacturer of the t:slim X2 insulin pump with Control-IQ AID technology. Competes for the same insulin-requiring patient population, though delivered via tubed pump rather than patch form factor. Tandem is also an investor in CeQur (Series C5).

TypeBroad incumbent
Description

Incumbent insulin pump manufacturer (MiniMed 780G AID system) with dominant hospital channel relationships and integrated CGM (Guardian) offering. Far larger and broader portfolio than CeQur's single patch product.

TypeDirect peer
Description

Markets V-Go, a wearable basal-bolus insulin patch that delivers continuous basal and on-demand bolus insulin. Most directly comparable by mechanism (wearable patch, mechanical bolus delivery) though V-Go provides basal coverage as well.

TypeDirect peer
Description

Swiss manufacturer of the mylife YpsoPump insulin pump and a long-standing CeQur investor. Comparable wearable/concealable insulin delivery device maker and a strategic partner/investor with potential channel conflict.

TypeBroad incumbent
Description

Continuous glucose monitor (CGM) market leader whose devices are increasingly integrated with insulin pump AID systems. Dexcom is part of the broader diabetes technology ecosystem CeQur operates in, and Darin Row (CeQur's VP Sales) joined from Dexcom.

TypeBroad incumbent
Description

Maker of FreeStyle Libre, the global CGM volume leader. Increasingly moving toward automated insulin delivery through partnerships (e.g., Tandem, Insulet), making Abbott a powerful adjacent incumbent shaping the same patient ecosystem.

8Bigfoot Biomedical
TypeEmerging player
Description

Diabetes-focused startup developing smart insulin pen systems and AID integrations. Targets the MDI population similar to CeQur but via connected pen rather than patch, positioning as an emerging alternative in the same 'simplify MDI' category.

TypeBroad incumbent
Description

Major insulin manufacturer (Humalog) and GLP-1 producer. CeQur Simplicity is FDA-cleared for use with Humalog, making Lilly a critical compatibility partner; Lilly's own diabetes device ambitions (e.g., connected pen ecosystem) create adjacent competition.

TypeBroad incumbent
Description

Major insulin manufacturer (NovoLog) and GLP-1 leader. CeQur Simplicity is cleared for use with NovoLog, making Novo Nordisk a key compatibility partner; the company's growing diabetes technology footprint creates ecosystem-level competitive dynamics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CeQur Simplicity

Wearable Insulin Delivery Devicesmyceqursimplicity.com

CeQur Simplicity is a private medical device company offering a wearable bolus insulin delivery patch for adults with Type 1 or Type 2 diabetes on multiple daily injections. The FDA-cleared device is dispensed via US retail pharmacies.

What CeQur Simplicity does

CeQur Simplicity is a privately held medical device company that designs, manufactures, and commercializes a wearable, disposable bolus insulin delivery patch for adults aged 21 and older with Type 1 or Type 2 diabetes who are on multiple daily injection (MDI) regimens. The company's core technology is a thin, low-profile patch that delivers rapid-acting mealtime insulin via a hidden, flexible cannula, eliminating the need for needle handling at each meal. The device holds 15 patents covering its bolus-only architecture, dosing lock safety mechanism, hidden cannula insertion, and two-button user interface, and is FDA 510(k)-cleared for up to 7 days of continuous wear with the most recent clearance extending wear duration from 4 days and adding a 1-unit dosing variant for more precise titration. The patch is compatible with Eli Lilly's Humalog (insulin lispro) and Novo Nordisk's NovoLog (insulin aspart) U-100 rapid-acting insulin analogues, which patients fill into the device themselves.

The company operates a prescription-based, pharmacy-benefit commercial model in the United States. Revenue is generated through hardware sales of the patch (sold as an 8-pack), dispensed via retail pharmacies with coverage on more than 85% of claims as a pharmacy benefit as of mid-2026. Commercial distribution combines an expanding US field sales force targeting endocrinologists, primary care physicians, and certified diabetes educators; clinical diabetes specialists supporting prescriber education; and the CeQur Cares inside-sales patient support team handling onboarding, insurance navigation, and copay enrollment (commercially insured patients can access a savings card limiting out-of-pocket to under $35 per month). Government channel sales to the VA and DoD are executed through Lovell Government Services, a Service-Disabled Veteran-Owned Small Business partner.

CeQur is headquartered in Horw, Switzerland, with US operational headquarters in Greenville, South Carolina, and a 40,000 sq ft automated cleanroom manufacturing facility in Marlborough, Massachusetts, completed in Q4 2024 with capacity to support 100,000 patients. The company has raised more than $335 million across five equity rounds, including a $100 million Series C5 in April 2021, a $120 million equity financing in January 2025, and a $100 million Series E in June 2026 led by Sanofi Ventures. More than 6,000 patients were actively using the device by mid-2025, and the patch has cumulatively replaced more than 10 million mealtime injections since launch. The commercial organization is led by CEO Bradley Paddock (appointed June 2019), CFO Mike Rubino, Chief Commercial Officer Lisa Furnish, and VP of Sales Darin Row (joined March 2025 from Dexcom).

CeQur Simplicity firmographics

Firmographics
Name
CeQur Simplicity
Legal name
CeQur SA
Website
https://myceqursimplicity.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
CeQur Simplicity is a private medical device company offering a wearable bolus insulin delivery patch for adults with Type 1 or Type 2 diabetes on multiple daily injections. The FDA-cleared device is dispensed via US retail pharmacies.
Ownership category
akta.pro rank

CeQur Simplicity industry classification

Industry
Product category
Wearable Insulin Delivery Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Wearable insulin patch
  • Mealtime insulin delivery
  • Diabetes medical device
  • Bolus insulin patch
  • FDA cleared insulin delivery

Where CeQur Simplicity is headquartered

Location

Headquarters

HQ city
Horw
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

CeQur Simplicity business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Insulin Delivery Device — Prescription Medical Device Sales: CeQur generates revenue primarily through the sale of its Simplicity bolus insulin delivery patch. The device is a prescription-only Class II medical device dispensed through retail pharmacies. Patients obtain the device via prescription from their healthcare provider and fill it at a pharmacy. Revenue is driven by prescription volume, patient adherence, and payer coverage. Commercial insurance, Medicare Part D, and cash-pay patients all contribute.

Pricing tiers

ModelBillingPrice
Unit PricingMonthlyStandard prescription — retail pharmacy (commercial insurance)
Unit PricingMonthlyStandard prescription — retail pharmacy (uninsured / cash pay)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

CeQur Simplicity product offering

Product offering

Core offering

CeQur Simplicity develops and manufactures a wearable, disposable bolus insulin delivery patch designed to replace multiple daily mealtime injections for adults with Type 1 or Type 2 diabetes. The device delivers rapid-acting insulin (Humalog or NovoLog) on demand via a hidden flexible cannula using a simple two-button interface, with FDA-cleared wear durations of up to 7 days.

Product overview

CeQur Simplicity is a single-product medical device company offering the CeQur Simplicity wearable insulin patch as its core product. The portfolio consists of the CeQur Simplicity patch (available in 2-unit and 1-unit dosing variants, with wear duration extended from 4 to 7 days), the reusable Inserter accessory, and the CeQur Cares patient support program. The patch is filled by users with their own prescribed rapid-acting insulin (Humalog U-100 or NovoLog U-100) and delivers on-demand bolus insulin subcutaneously via a flexible cannula. The company also offers a copay savings card for commercially insured patients. The product is sold as an 8-pack of 4-day patches (now expanding to 7-day variants) and is covered as a pharmacy benefit by most commercial and Medicare Part D plans.

Differentiator

Problem solved

Functional benefit

Products and services

  • CeQur Simplicity Wearable Insulin Patch A disposable wearable patch that delivers mealtime and correction bolus insulin via a soft, flexible cannula. Users fill the patch with up to 200 units of rapid-acting insulin (Humalog U-100 or NovoLog U-100) and self-administer 2-unit doses by squeezing two buttons. The patch is FDA-cleared for wear up to 7 days and eliminates the need for multiple daily injections.
  • CeQur Simplicity 1-Unit Dosing Device A variant of the CeQur Simplicity patch delivering 1-unit increments of rapid-acting insulin for more precise titration in patients requiring tighter glycemic control or lower mealtime insulin doses.
  • CeQur Simplicity Inserter A reusable handheld device used to apply the CeQur Simplicity patch to the abdomen. Measures 3.7 inches long, 2.2 inches wide, and 1.8 inches high, weighing 2.5 ounces, and is cleanable with soapy water.

Quantifiable outcome

  • A1C reduction of 1.7% in adults with Type 1 or Type 2 diabetes on multiple daily injections
  • +1 more outcomes

Companies that use CeQur Simplicity

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

CeQur Simplicity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

CeQur Simplicity partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Lovell Government ServicescoreChannel Partner/ Reseller/ DistributorLovell Government Services is a Service-Disabled Veteran-Owned Small Business (SDVOSB) that serves as CeQur's channel partner for sales into the Veterans Affairs (VA) and Department of Defense (DoD) healthcare systems. CeQur has partnered with Lovell to expand access to the Simplicity bolus insulin delivery patch for eligible veterans and active-duty military patients with diabetes managed on multiple daily injections. The partnership enables CeQur to comply with government contracting requirements and access a specialized distribution channel.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

CeQur Simplicity competitors and assessment

Company assessment

Direct peers

  • Insulet Corporation: Maker of the Omnipod tubeless patch pump, the closest direct competitor to CeQur in the wearable insulin delivery category. Omnipod 5 is an integrated AID system, while CeQur is bolus-only — both target patients seeking tubeless, on-body insulin delivery via patch form factor.
  • Tandem Diabetes Care: Manufacturer of the t:slim X2 insulin pump with Control-IQ AID technology. Competes for the same insulin-requiring patient population, though delivered via tubed pump rather than patch form factor. Tandem is also an investor in CeQur (Series C5).
  • MannKind Corporation (V-Go): Markets V-Go, a wearable basal-bolus insulin patch that delivers continuous basal and on-demand bolus insulin. Most directly comparable by mechanism (wearable patch, mechanical bolus delivery) though V-Go provides basal coverage as well.
  • Ypsomed: Swiss manufacturer of the mylife YpsoPump insulin pump and a long-standing CeQur investor. Comparable wearable/concealable insulin delivery device maker and a strategic partner/investor with potential channel conflict.

Broad incumbents

  • Medtronic Diabetes: Incumbent insulin pump manufacturer (MiniMed 780G AID system) with dominant hospital channel relationships and integrated CGM (Guardian) offering. Far larger and broader portfolio than CeQur's single patch product.
  • Dexcom: Continuous glucose monitor (CGM) market leader whose devices are increasingly integrated with insulin pump AID systems. Dexcom is part of the broader diabetes technology ecosystem CeQur operates in, and Darin Row (CeQur's VP Sales) joined from Dexcom.
  • Abbott Diabetes Care: Maker of FreeStyle Libre, the global CGM volume leader. Increasingly moving toward automated insulin delivery through partnerships (e.g., Tandem, Insulet), making Abbott a powerful adjacent incumbent shaping the same patient ecosystem.
  • Eli Lilly: Major insulin manufacturer (Humalog) and GLP-1 producer. CeQur Simplicity is FDA-cleared for use with Humalog, making Lilly a critical compatibility partner; Lilly's own diabetes device ambitions (e.g., connected pen ecosystem) create adjacent competition.
  • Novo Nordisk: Major insulin manufacturer (NovoLog) and GLP-1 leader. CeQur Simplicity is cleared for use with NovoLog, making Novo Nordisk a key compatibility partner; the company's growing diabetes technology footprint creates ecosystem-level competitive dynamics.

Emerging players

  • Bigfoot Biomedical: Diabetes-focused startup developing smart insulin pen systems and AID integrations. Targets the MDI population similar to CeQur but via connected pen rather than patch, positioning as an emerging alternative in the same 'simplify MDI' category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

CeQur Simplicity social profiles

Digital presence

CeQur Simplicity compliance and trust

Trust signal

Compliance2 records

CeQur Simplicity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CeQur Simplicity leadership team

Management profile

Number of profiles

Profiles10 records

CeQur Simplicity funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CeQur Simplicity M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CeQur Simplicity

What does CeQur Simplicity do?

CeQur Simplicity develops and manufactures a wearable, disposable bolus insulin delivery patch designed to replace multiple daily mealtime injections for adults with Type 1 or Type 2 diabetes. The device delivers rapid-acting insulin (Humalog or NovoLog) on demand via a hidden flexible cannula using a simple two-button interface, with FDA-cleared wear durations of up to 7 days.

Is CeQur Simplicity a public or private company?

CeQur Simplicity is a private company. It is classified as venture growth investor backed and is currently operating.

When was CeQur Simplicity founded?

CeQur Simplicity was founded in 2018. It employs 101 to 250 people.

Where is CeQur Simplicity based?

CeQur Simplicity is headquartered in Horw, Switzerland, in the Europe region.

How does CeQur Simplicity make money?

One revenue line is on record: insulin Delivery Device — Prescription Medical Device Sales.

Who are CeQur Simplicity's main competitors?

Direct peers on record are Insulet Corporation, Tandem Diabetes Care, MannKind Corporation (V-Go) and Ypsomed. Broad incumbents are Medtronic Diabetes, Dexcom, Abbott Diabetes Care, Eli Lilly and Novo Nordisk. Bigfoot Biomedical is listed as an emerging player.

Does CeQur Simplicity have an API?

No public API is recorded for CeQur Simplicity.

What industry is CeQur Simplicity in?

CeQur Simplicity's product category is Wearable Insulin Delivery Devices. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery. Its NAICS code is 3391 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TechRepublicWearable Insulin Patch Could Replace Up to 21 Mealtime ShotsCeQur announced its updated Simplicity insulin patch is available in the US, offering up to seven days of wear and potentially replacing up to 21 mealtime injections. The patch delivers prescribed doses via two buttons, with improved capacity and dosing increments over the previous version. It does not measure blood sugar or respond to smartwatch readings.PR NewswireCeQur Simplicity Wearable Insulin Patch Now Available Nationally with Up to 7 Days of Wear and 1-Unit Dosing: Taking on the Mealtime Insulin ProblemCeQur announced national availability of its Simplicity wearable insulin patch with FDA-cleared 7-day wear and a new 1-unit dosing option. A Harris Poll survey of 409 U.S. adults found 51% miss or skip mealtime insulin doses, and 70% of those missed doses in public settings.FinancialContent Business PageMealtime insulin injections are a problem: A wearable insulin patch can helpA CeQur/Harris Poll survey found 51% of U.S. adults with mealtime insulin miss doses, often in public settings. The survey also showed 54% report psychological impact and 61% of employed respondents say it affects their job. CeQur Simplicity, a wearable patch, offers two dosing options in November to replace 21 injections.Tech.euEuropean tech weekly recap: €2.8B in deals and May's highlightsEuropean tech startups raised €10.5 billion across 258 funding deals in May, with the UK leading at €7.9 billion and cloud companies top-funded at €3 billion. Exit activity reached 39 transactions, reflecting improved market liquidity and investor confidence.BioWorldFinancings for June 12, 2026Biopharma and med-tech companies raised money in public or private financings on June 12, 2026. The companies listed include Atossa, Cequr, Edesa, Humacyte, Ideaya, Kardigan, Nyxoah, and Thruflo.Pulse 2.0CeQur Raises $100 Million Series E To Expand Growth Of CeQur Simplicity Insulin PatchCeQur, a medical device company focused on simplifying mealtime insulin delivery for people with diabetes, announced the closing of a $100 million Series E financing round backed by continued investor confidence in its commercial progress and clinical results. The funding will be used to accelerate growth across commercial operations, including expanding the company's field sales organization and strengthening relationships with healthcare providers and diabetes specialists. The company is also preparing to broaden its CeQur Simplicity product line with extended seven-day wear capabilities and additional dosing options to serve a wider patient population.Fastdata极数瑞士胰岛素输送器研发商瑞士 胰岛素输送器研发商CeQur完成1亿美元E轮融资 – Fastdata极数CeQur, a Swiss insulin delivery device developer, completed a $100 million Series E financing. The company is developing the CeQur insulin infusion device for type 2 diabetes patients needing intensified therapy but avoiding multiple daily injections.MyceqursimplicityCeQur® Closes $100 Million Series E, Backed by Commercial Momentum and Growing Demand for CeQur Simplicity™CeQur closed a $100 million Series E financing round to accelerate commercial growth. The capital will expand its field sales team and support CeQur Simplicity's extended 7-day wear and 1- and 2-unit options. The company cites strong adoption and clinical evidence as drivers.MassDeviceCeQur closes $100M Series E to support mealtime insulin patchCeQur, a Horw, Switzerland-based medical device company, closed a $100 million Series E financing round to support its Simplicity mealtime insulin patch pump system. The funding follows recent FDA clearances expanding the device's continuous wear duration from three days to seven days and approving a new 1-unit device variant. The company had previously raised $115 million in April 2021 to support its pilot commercial launch and manufacturing scale-up.DrugdeliverybusinessCeQur closes $100M Series E to support mealtime insulin patchCeQur closed a $100 million Series E financing round to support its Simplicity mealtime insulin patch pump system, which is a wearable, disposable bolus insulin delivery device. The company, based in Horw, Switzerland, recently received FDA clearance for an extended wear time of up to seven days and approval for a new 1-unit device. CeQur plans to use the proceeds to expand its field sales team and accelerate commercial growth across providers and diabetes care specialists.